| Activin A Receptor Type 2A |
|---|
| Gene Symbol | ACVR2A |
| Full Name | Activin A Receptor Type 2A |
| Chromosome | 2q22.3 |
| NCBI Gene ID | [92](https://www.ncbi.nlm.nih.gov/gene/92) |
| OMIM | [102581](https://www.omim.org/entry/102581) |
| Ensembl ID | ENSG00000198893 |
| UniProt ID | [P27037](https://www.uniprot.org/uniprot/P27037) |
| Protein Length | 513 amino acids |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Cancer |
ACVR2A (Activin A Receptor Type 2A) is a member of the TGF-beta superfamily of serine/threonine kinase receptors. It functions as a type II receptor that binds activin A, activin B, and other TGF-beta superfamily ligands, forming receptor complexes with type I receptors (ALK4/ACVR1B) to transduce signals via SMAD2/3 phosphorylation .
ACVR2A plays critical roles in neural development, synaptic plasticity, neurogenesis, and neuronal survival. The protein is expressed throughout the brain in both neurons and glia, with particularly high expression in the hippocampus, cerebral cortex, and substantia nigra. Dysregulation of ACVR2A signaling has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions .
¶ Structure and Biochemistry
¶ Protein Domain Architecture
ACVR2A possesses the canonical structure of a type II TGF-beta receptor:
- Extracellular domain (~180 aa): Ligand-binding region containing conserved cysteine residues that form disulfide bonds for proper folding
- Transmembrane domain (~30 aa): Single-pass alpha-helical transmembrane segment
- Intracellular serine/threonine kinase domain (~270 aa): Catalytic domain with kinase activity
The kinase domain contains the conserved activation segment and regulatory sites that mediate downstream signaling through SMAD proteins.
¶ Ligand Binding and Receptor Activation
ACVR2A binds multiple TGF-beta superfamily ligands:
- Activin A (INHBA homodimer): Primary ligand in the nervous system
- Activin B (INHBB homodimer): Alternative ligand with overlapping functions
- Inhibins: Can form complexes with ACVR2A to modulate signaling
- BMPs: Bone morphogenetic proteins can also activate ACVR2A at higher concentrations
The activation mechanism follows the canonical TGF-beta receptor pathway:
- Ligand binding: Activin A binds to the extracellular domain of ACVR2A
- Type I recruitment: ACVR2A recruits a type I receptor (ACVR1B/ALK4) to the complex
- Phosphorylation: ACVR2A phosphorylates the type I receptor kinase domain
- SMAD activation: The activated type I receptor phosphorylates SMAD2/3
- Nuclear translocation: SMAD2/3 complexes with SMAD4 and translocates to the nucleus
ACVR2A undergoes several post-translational modifications:
- Phosphorylation: Multiple serine/threonine residues in the kinase domain are phosphorylated during activation
- Glycosylation: N-linked glycosylation in the extracellular domain affects ligand binding
- Ubiquitination: Regulates receptor turnover and degradation
- Sumoylation: Modulates receptor stability and signaling
During development, ACVR2A signaling regulates multiple aspects of neurodevelopment :
- Neural tube patterning: Controls dorsal-ventral axis specification
- Neurogenesis: Regulates neural progenitor cell proliferation and differentiation
- Neuronal migration: Guides post-mitotic neurons to their final positions
- Axon guidance: Provides repulsive cues for growing axons
- Synaptogenesis: Controls the formation and refinement of synaptic connections
In the adult brain, ACVR2A continues to play important roles in synaptic function :
- Activin A enhances LTP in hippocampal neurons
- ACVR2A is required for the consolidation phase of LTP
- SMAD2/3 signaling participates in transcription-dependent LTP maintenance
- Activin modulates LTD induction in certain paradigms
- ACVR2A regulates AMPA receptor internalization
- Participates in synaptic scaling and homeostatic plasticity
- Controls dendritic spine morphology
- Regulates spine density and stability
- Modulates synaptic strength through structural plasticity
ACVR2A signaling regulates adult neurogenesis in the hippocampus :
- Promotes neural progenitor cell (NPC) proliferation in the subventricular zone and dentate gyrus
- Controls differentiation toward neuronal fate
- Supports survival of newly generated neurons
- Facilitates integration into existing circuits
ACVR2A activation provides neuroprotective effects through multiple mechanisms :
- Anti-apoptotic signaling: Promotes neuronal survival through PI3K/AKT pathway activation
- Anti-excitotoxic effects: Protects against glutamate-induced excitotoxicity
- Anti-inflammatory actions: Modulates microglial activation and cytokine production
- Oxidative stress reduction: Enhances antioxidant defenses
ACVR2A exhibits widespread expression throughout the central nervous system:
- Hippocampus: High expression in CA1, CA3, and dentate gyrus neurons
- Cerebral cortex: Enriched in layers II-VI pyramidal neurons
- Substantia nigra: Expressed in dopaminergic neurons of the pars compacta
- Cerebellum: Purkinje cells show high expression
- Hypothalamus: Present in various nuclei including the arcuate nucleus
- Amygdala: Moderate expression in central and basal nuclei
¶ Cellular and Subcellular Localization
Within the brain, ACVR2A is expressed in:
- Neurons: Both excitatory pyramidal neurons and inhibitory interneurons
- Astrocytes: GFAP-positive astrocytes throughout the brain
- Microglia: Resting and activated microglial cells
- Oligodendrocytes: Pre-myelinating and mature oligodendrocytes
Subcellular localization includes:
- Plasma membrane: Primary receptor location
- Endosomes: Signaling compartments for receptor internalization
- Nucleus: Some SMAD-dependent nuclear localization
ACVR2A dysfunction contributes to Alzheimer's disease pathogenesis through multiple mechanisms :
- Activin A levels are altered in AD brains and may modulate amyloid pathology
- ACVR2A signaling can influence APP processing
- Impaired SMAD signaling affects neuronal vulnerability to Aβ toxicity
- SMAD2/3 signaling dysregulated in tauopathy
- ACVR2A signaling intersects with tau phosphorylation pathways
- Altered activin signaling may contribute to tau spreading
- Loss of activin/ACVR2A signaling contributes to synaptic failure
- Impaired LTP and memory consolidation
- Reduced dendritic spine density in AD models
- Activin signaling modulates microglial activation
- ACVR2A dysfunction may exacerbate neuroinflammation
- Altered cytokine regulation in AD brains
ACVR2A has significant implications for Parkinson's disease :
- Activin A promotes survival of dopaminergic neurons
- ACVR2A variants may modify PD risk
- Protective effects against 6-OHDA and MPTP toxicity
- TGF-beta signaling interacts with alpha-synuclein aggregation
- ACVR2A may influence alpha-synuclein toxicity
- Protective effects against dopaminergic degeneration
- Activin modulates microglial activation states
- May reduce pro-inflammatory cytokine production
- Potential therapeutic target for neuroinflammation
ACVR2A is relevant to ALS through :
- Motor neuron survival promotion
- Glial cell interactions
- Neuroinflammatory modulation
- Connection with BMP signaling pathways
Age-related changes in ACVR2A signaling contribute to neuronal vulnerability :
- Reduced ACVR2A expression in aging brain
- Impaired SMAD signaling with age
- Decreased neurogenic capacity
- Increased neuroinflammation
flowchart TD
A["Activin A"] --> B["ACVR2A"]
B --> C["ACVR1B/ALK4"]
C --> D["SMAD2/3 Phosphorylation"]
D --> E["SMAD2/3-SMAD4 Complex"]
E --> F["Nuclear Translocation"]
F --> G["Gene Transcription"]
G --> H["Neuroprotection<br/>Synaptic Plasticity<br/>Neurogenesis"]
style A fill:#e1f5fe,stroke:#333
style H fill:#c8e6c9,stroke:#333
ACVR2A signaling intersects with multiple other pathways :
| Pathway |
Interaction |
| BMP signaling |
Shared SMAD4, competitive and cooperative |
| PI3K/AKT |
Downstream survival signaling |
| MAPK/ERK |
Non-SMAD pathway activation |
| Wnt signaling |
Cross-inhibition at transcriptional level |
ACVR2A represents a promising therapeutic target for neurodegenerative diseases :
- Recombinant activin A: Protein-based delivery for neuroprotection
- Small molecule agonists: Brain-penetrant activin mimetics
- Gene therapy: Viral vector-mediated ACVR2B expression
- ACVR2A overexpression: Increase receptor levels for enhanced signaling
- Receptor stabilization: Prevent degradation and enhance signaling
- Decoy receptors: Soluble ACVR2A-Fc fusion proteins
- SMAD2/3 pathway activators: Target downstream of receptor
- Inhibitory SMAD7 blockade: Reduce negative feedback
- SMAD4 enhancement: Improve nuclear translocation
¶ Challenges and Considerations
- Delivery: Getting therapeutics across the blood-brain barrier
- Specificity: Avoiding off-target effects on related receptors
- Timing: Optimal intervention window in disease progression
- Dose optimization: Balancing efficacy with potential side effects
- Neuron-specific ACVR2A functions: Cell type-specific roles in the brain
- Effector specificity: Downstream effectors specific to neuronal ACVR2A
- Disease mechanisms: How ACVR2A dysfunction contributes to specific pathologies
- Therapeutic windows: Optimal timing for intervention
- Single-cell analysis: ACVR2A expression in specific neuronal subtypes
- Structural studies: ACVR2A-ligand and ACVR2A-ACVR1B complex structures
- Biomarkers: ACVR2A as disease biomarker or therapeutic response indicator
- Combination therapies: ACVR2A targeting with other disease-modifying approaches
- Activin A signaling in Alzheimer's disease (2019) — Brain Pathology
- ACVR2A and dopaminergic neuron protection (2018) — Movement Disorders
- Activin signaling in neurogenesis (2020) — Trends in Neurosciences
- SMAD2/3 dysfunction in neurodegeneration (2019) — Neurobiology of Aging
- Activin and synaptic plasticity (2017) — Neuroscience
- Neuroinflammation and activin signaling (2020) — Frontiers in Cellular Neuroscience
- Activin A as neuroprotective factor (2019) — Pharmacology & Therapeutics
- TGF-beta superfamily in Parkinson's disease (2021) — Cellular and Molecular Neurobiology
- ACVR2A in neural stem cell fate (2019) — Stem Cells
- Activin signaling in adult neurogenesis (2020) — Cell Stem Cell